Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Account Payables: 2010-2025

Historic Change in Account Payables for Catalyst Pharmaceuticals (CPRX) over the last 14 years, with Sep 2025 value amounting to $3.6 million.

  • Catalyst Pharmaceuticals' Change in Account Payables fell 19.77% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.5 million, marking a year-over-year decrease of 135.42%. This contributed to the annual value of $1.8 million for FY2024, which is 83.38% down from last year.
  • Catalyst Pharmaceuticals' Change in Account Payables amounted to $3.6 million in Q3 2025, which was up 162.94% from -$5.7 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Change in Account Payables ranged from a high of $10.2 million in Q4 2023 and a low of -$5.7 million during Q2 2025.
  • Its 3-year average for Change in Account Payables is $465,545, with a median of $177,000 in 2023.
  • Data for Catalyst Pharmaceuticals' Change in Account Payables shows a peak YoY increase of 8,937.50% (in 2022) and a maximum YoY decrease of 873.70% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' Change in Account Payables stood at $16,000 in 2021, then surged by 8,937.50% to $1.4 million in 2022, then spiked by 605.19% to $10.2 million in 2023, then slumped by 50.67% to $5.0 million in 2024, then fell by 19.77% to $3.6 million in 2025.
  • Its Change in Account Payables was $3.6 million in Q3 2025, compared to -$5.7 million in Q2 2025 and -$5.4 million in Q1 2025.